HLB Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Pharmaceutical makes prescription medicines and supplies contract manufacturing services to other drug companies, while also distributing health-functional foods.
It is listed on KOSDAQ, Korea's tech and small-cap board, and supplies a broad portfolio of prescription drugs through a commissioned-sales model, where partner companies handle field promotion. Its contract manufacturing business is shifting from general over-the-counter medicines toward higher-value prescription drugs, supported by investment in bioequivalence testing.
Summary is AI-generated and may contain errors · figures from DART filings
The company joined the HLB Group in October of a recent year and subsequently acquired a full stake in Shinhwa Advance, adding pharmaceutical distribution as a new business line.
HLB Pharmaceutical in five facts
What does HLB Pharmaceutical do?
HLB Pharmaceutical makes prescription medicines and supplies contract manufacturing services to other drug companies, while also distributing health-functional foods.
Where is HLB Pharmaceutical listed and in which sector?
HLB Pharmaceutical (Korean name: HLB제약) trades under KRX code 047920 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is HLB Pharmaceutical?
Its market capitalisation was US$347.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, HLB Pharmaceutical reported revenue of US$155.2M, operating profit of US$802.9K and net income of US$3.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 50.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 21
- Investor relations (IR) meetingOct 12
- DisclosureOct 1
- Report on large shareholdings (5% rule) (standard)Sep 28
- Report on securities held by executives/major shareholdersSep 28
- Securities issuance results (voluntary)Sep 18
- Securities issuance reportSep 18
- Subscription results of rights offering or equity-linked bonds (voluntary)
HLB Pharma Co., Ltd. completed a paid-in capital increase through shareholder allocation with general public offering on September 16, 2026, issuing 10,762,332 planned shares with a total subscription rate of 338.41% (36,421,052 shares subscribed). New shares are scheduled to be listed on October 7, 2026.
Capital raise · Sep 17 - [Amended] Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Sep 15 · 2 versions
- Report on large shareholdings (5% rule) (standard)Sep 9
- Rights offering: final issue price setCapital raise · Sep 8
- [Amended] ProspectusSep 8
- [Terms finalized] Securities registration statement (equity)Sep 8
- [Amended] Material event report (rights offering)
HLB Pharmaceutical updated the terms of a new share issuance to raise US$45.4M, about 14.2% of its market value.
Capital raise · Sep 8 · 4 versions - Report on large shareholdings (5% rule) (standard)Sep 3
- [Amended] ProspectusSep 1
- DisclosureSep 1
- [Amended] Securities registration statement (equity)Aug 31
- Report on large shareholdings (5% rule) (standard)Aug 31
- Ex-rights (rights offering)
HLB Pharmaceutical's shares will go ex-rights on 2026-08-04 at a base price of US$5.34 ahead of a rights offering.
Capital raise · Aug 3 - [Amended] Rights offering: round 1 issue price set
HLB Pharmaceutical corrected a clerical error updating the website URL referenced for the final issue price announcement from immuneoncia.com to hlbpharma.co.kr; the round-1 issue price of US$3.96 per share for 10,762,332 new common shares (par value US$0.35), calculated as of 2026-07-31, is unchanged.
Capital raise · Aug 3 · 2 versions - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Pharmaceutical updated its previously filed consolidated results for FY2025: revenue of US$140M (+50% year on year), operating profit of US$726K (−27.8% year on year) and net income of US$3.12M (+126.3% year on year).
Earnings · Mar 10 · 2 versions